Judith S Sebolt-Leopold

Summary

Country: USA

Publications

  1. ncbi MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48103, USA
    Curr Pharm Des 10:1907-14. 2004
  2. ncbi Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention
    Roman Herrera
    Department of Cancer Molecular Sciences, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Trends Mol Med 8:S27-31. 2002
  3. ncbi Mechanisms of drug inhibition of signalling molecules
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Nature 441:457-62. 2006
  4. ncbi Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
    Judith S Sebolt-Leopold
    Oncovera Therapeutics, Ann Arbor, Michigan 48103, USA
    Clin Cancer Res 14:3651-6. 2008
  5. ncbi Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition
    Judith S Sebolt-Leopold
    Cancer Molecular Sciences Department, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Methods Mol Med 85:31-8. 2003
  6. ncbi Targeting the mitogen-activated protein kinase cascade to treat cancer
    Judith S Sebolt-Leopold
    Molecular Sciences and Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Nat Rev Cancer 4:937-47. 2004
  7. ncbi The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer
    Patrick J Klein
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Neoplasia 8:1-8. 2006
  8. ncbi Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    John Rinehart
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Oncol 22:4456-62. 2004
  9. ncbi The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor 48105, USA
    Recent Results Cancer Res 172:155-67. 2007
  10. ncbi 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase
    Julie A Spicer
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    J Med Chem 50:5090-102. 2007

Collaborators

  • Patricia M LoRusso
  • W A Denny
  • A A Adjei
  • Jeffrey F Ohren
  • Roman Herrera
  • Julie A Spicer
  • Charles Omer
  • Patrick J Klein
  • John Rinehart
  • Daniel F Ortwine
  • Ronald L Merriman
  • Alexander G Pavlovsky
  • Jared B J Milbank
  • Shannon L Black
  • Stephen D Barrett
  • Mark S Plummer
  • John Quin
  • Sally Pryzbranowski
  • Heidi S Camp
  • Aurash B Shahripour
  • Haile Tecle
  • Nadia Esmaeil
  • Joseph S Warmus
  • Cathlin M Flamme
  • Richard C Gowan
  • Gordon W Rewcastle
  • Michael D Kaufman
  • Kelley Moore
  • Christopher E Whitehead
  • Eric A Wiebke
  • C Max Schmidt
  • Michele T Yip-Schneider
  • Chad A Wiesenauer
  • Earl A Gage
  • Jennifer N Choi
  • Yufang Wang
  • Ronald B Natale
  • David Y Mitchell
  • J Randolph Hecht
  • Mark B Meyer
  • David Waterhouse
  • Oday Hamid
  • Peggy Asbury
  • Eric P Kaldjian
  • Mary Varterasian
  • Stephen Gulyas

Detail Information

Publications11

  1. ncbi MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48103, USA
    Curr Pharm Des 10:1907-14. 2004
    ..The evaluation of sufficiently potent and selective MEK inhibitors in well-designed clinical trials is critical for ultimate validation of MEK as a molecular-based anticancer drug target...
  2. ncbi Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention
    Roman Herrera
    Department of Cancer Molecular Sciences, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Trends Mol Med 8:S27-31. 2002
    ..While we await answers on their ultimate therapeutic use, the availability of translational assays for monitoring target suppression will no doubt play a significant role in optimizing our chances of success...
  3. ncbi Mechanisms of drug inhibition of signalling molecules
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Nature 441:457-62. 2006
    ..However, despite uncertainty over precise or dominant mechanisms of action, especially for compounds targeting multiple gene products, emerging agents are producing significant therapeutic advances against a broad range of human cancers...
  4. ncbi Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
    Judith S Sebolt-Leopold
    Oncovera Therapeutics, Ann Arbor, Michigan 48103, USA
    Clin Cancer Res 14:3651-6. 2008
    ....
  5. ncbi Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition
    Judith S Sebolt-Leopold
    Cancer Molecular Sciences Department, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Methods Mol Med 85:31-8. 2003
  6. ncbi Targeting the mitogen-activated protein kinase cascade to treat cancer
    Judith S Sebolt-Leopold
    Molecular Sciences and Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Nat Rev Cancer 4:937-47. 2004
    ..What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?..
  7. ncbi The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer
    Patrick J Klein
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Neoplasia 8:1-8. 2006
    ..Thus, we speculate that the degree of success of MEK targeted treatment in HCC and other cancers may, in part, depend on the discovery of mechanisms governing MEK inhibitor signaling resistance...
  8. ncbi Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    John Rinehart
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Oncol 22:4456-62. 2004
    ....
  9. ncbi The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment
    Judith S Sebolt-Leopold
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor 48105, USA
    Recent Results Cancer Res 172:155-67. 2007
  10. ncbi 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase
    Julie A Spicer
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    J Med Chem 50:5090-102. 2007
    ..Most notably, pyridone 27 was found to be more potent than 1 in vitro and produced a 100% response rate at a lower dose than 1, when tested for in vivo efficacy in animals bearing C26 tumors...
  11. ncbi Inhibitors of Bcr-abl... breaking new ground again
    Jeffrey F Ohren
    Nat Chem Biol 2:63-4. 2006